Paragon Care (ASX:PGC): Is the Market Underestimating This Healthcare Growth Story?

Aditi Sarkar

02 September 2026 04:09 PM AEST

Paragon Care (ASX:PGC): Is the Market Underestimating This Healthcare Growth Story?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Paragon Care provides healthcare products and services across pharmaceuticals, medical devices and consumables.
FY26 results showed underlying Revenue and Earnings growth following its expanded healthcare distribution platform.
The company continues focusing on integration, cash generation and balance-sheet management.
Future performance depends on Merger synergies, Debt reduction and sustainable earnings growth.

Paragon Care (ASX:PGC) is a healthcare products and services group operating across pharmaceuticals, medical devices and consumables markets. The company has expanded significantly through its roll-up strategy, including the merger with CH2 (Clifford Hallam Healthcare), creating a larger healthcare distribution platform across Australia and the broader region.

The scale of the enlarged Business provides opportunities through purchasing efficiencies and broader customer networks, although healthcare distribution typically operates with lower margins and requires careful management of Working Capital and debt.

Latest Development

Paragon Care (ASX:PGC) released its FY26 full-year results on 26 August 2026. Underlying revenue was approximately A$3.7 billion, with management highlighting normalised growth of around 6.7%.

Underlying EBITDA increased approximately 7.4% on a normalised basis to A$97.2 million, while underlying net profit after tax was approximately A$26 million.

The statutory result was weaker, with statutory EBITDA of A$50.8 million and a statutory net loss of approximately A$16 million, mainly due to a A$38 million provision related to the Infinity Group.

Net debt was approximately A$243 million, equivalent to around 2.5 times EBITDA, while Operating Cash Flow increased to A$29.1 million. The company did not declare a Dividend for FY26 and indicated that the dividend position would be reviewed during the first half.

Financial Performance

The difference between underlying and statutory results remains an important Factor when assessing Paragon Care’s (ASX:PGC) FY26 performance.

Underlying figures reflected moderate growth in revenue and earnings, while the statutory loss was primarily affected by one-off provisions. The improvement in operating cash flow was a key development for a healthcare distribution business where inventory management and cash conversion are important factors.

The company’s Leverage position of approximately 2.5 times EBITDA highlights the importance of delivering integration benefits and maintaining disciplined cash management.

The decision not to declare a dividend for FY26 reflects a focus on strengthening the Balance Sheet and managing the integration process following the company’s expansion.

What Could Drive the Shares Next?

The key growth drivers for Paragon Care (ASX:PGC) include successful delivery of merger synergies, continued underlying revenue growth and progress in reducing debt levels.

A return to dividend payments following the company’s review would provide an indication of improved balance-sheet confidence.

Demonstrating that the expanded healthcare distribution platform can generate stronger margins, improved cash flow and operational efficiencies would be an important factor supporting future growth expectations.

Key Risks

Paragon Care (ASX:PGC) faces execution risks associated with integrating a large healthcare distribution platform. The A$38 million Infinity Group provision highlights how specific issues can affect statutory financial outcomes.

Healthcare distribution remains a lower-margin industry, making cost control, inventory management and operational efficiency important considerations.

The company’s debt position, dividend suspension and exposure to input-cost movements also remain factors investors will continue monitoring.

Investor Outlook

Paragon Care (ASX:PGC) delivered a mixed FY26 result, combining underlying earnings growth and stronger cash flow with a statutory loss driven by a significant provision and a notable debt position.

The company’s future trajectory will depend on successful integration, reducing leverage and demonstrating that scale can translate into stronger financial performance.

Progress on merger synergies, debt reduction and cash conversion will be key indicators of whether the company can unlock further value from its healthcare platform.

FAQs

Q: What does Paragon Care do?

A:Paragon Care distributes healthcare products including pharmaceuticals, medical devices and consumables.

Q: What was the key feature of Paragon Care’s FY26 result?

A:The company reported underlying growth and improved operating cash flow, while statutory results were affected by a significant provision.

Q: Why is the CH2 merger important for Paragon Care?

A:The merger expanded the company’s healthcare distribution scale and customer network.

Q: What are the key growth drivers for Paragon Care?

A:Integration benefits, debt reduction, earnings growth and potential dividend reinstatement are key drivers.

Q: What are the main risks for Paragon Care?

A:Key risks include integration challenges, debt levels, margin pressure and execution risks.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.